Last Updated: August 11, 2026

Pharmobedient Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Pharmobedient
International Patents:21
US Patents:1
Tradenames:248
Ingredients:236
NDAs:321

Drugs and US Patents for Pharmobedient

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmobedient LIOTHYRONINE SODIUM liothyronine sodium TABLET;ORAL 090326-002 Jul 14, 2009 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient ROPINIROLE HYDROCHLORIDE ropinirole hydrochloride TABLET;ORAL 078881-006 May 5, 2008 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient CHLORTHALIDONE chlorthalidone TABLET;ORAL 212878-001 Feb 24, 2022 AB RX No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient METFORMIN HYDROCHLORIDE metformin hydrochloride TABLET;ORAL 075976-003 Jan 24, 2002 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient DIDANOSINE didanosine CAPSULE, DELAYED REL PELLETS;ORAL 090788-001 Apr 8, 2010 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient FLUVASTATIN SODIUM fluvastatin sodium TABLET, EXTENDED RELEASE;ORAL 202458-001 Sep 11, 2015 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient LIDOCAINE lidocaine PATCH;TOPICAL 202346-001 Aug 7, 2015 AB RX No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pharmobedient

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmobedient DEMADEX torsemide TABLET;ORAL 020136-003 Aug 23, 1993 RE30633 ⤷  Start Trial
Pharmobedient OLUX E clobetasol propionate AEROSOL, FOAM;TOPICAL 022013-001 Jan 12, 2007 8,962,000 ⤷  Start Trial
Pharmobedient ZOVIRAX acyclovir TABLET;ORAL 020089-001 Apr 30, 1991 4,199,574 ⤷  Start Trial
Pharmobedient DEMADEX torsemide TABLET;ORAL 020136-002 Aug 23, 1993 RE34672 ⤷  Start Trial
Pharmobedient DEMADEX torsemide TABLET;ORAL 020136-001 Aug 23, 1993 RE34672 ⤷  Start Trial
Pharmobedient DEMADEX torsemide TABLET;ORAL 020136-003 Aug 23, 1993 RE34672 ⤷  Start Trial
Pharmobedient DUONEB albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 020950-001 Mar 21, 2001 6,632,842 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PHARMOBEDIENT drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Foam 0.05% ➤ Subscribe 2005-06-27
➤ Subscribe Foam 0.12% ➤ Subscribe 2007-08-10
➤ Subscribe Inhalation Solution 0.021% and 0.042% ➤ Subscribe 2005-10-19

Supplementary Protection Certificates for Pharmobedient Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2487166 2016/061 Ireland ⤷  Start Trial PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119
1744764 18C1047 France ⤷  Start Trial PRODUCT NAME: DAUNORUBICINE + CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
1539166 2013/055 Ireland ⤷  Start Trial PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
0720599 300689 Netherlands ⤷  Start Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0136011 99C0003 Belgium ⤷  Start Trial PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0273277 96C0039 Belgium ⤷  Start Trial PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 19960508
1853250 C300673 Netherlands ⤷  Start Trial PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

PHARMOBEDIENT Competitive Landscape Analysis: Market Position, IP Strength, and Strategic Moves

Last updated: July 10, 2026

Executive summary: PHARMOBEDIENT is not identifiable as a specific FDA-approved drug product, biologic, or active ingredient from the information provided. Without a determinable drug identity (active ingredient, brand name, sponsor/MAH, dosage form, and FDA application), no accurate Orange Book status, patent estate, exclusivity windows, Paragraph IV risk, or litigation can be mapped to support a competitive landscape assessment.

What is PHARMOBEDIENT in the US market, and who manufactures it?

Answer: Not determined from the provided input.

What active ingredient does PHARMOBEDIENT contain?

Not determined.

Is PHARMOBEDIENT an NDA, ANDA, BLA, or OTC product?

Not determined.

What dosage forms and strengths exist?

Not determined.

What is the Orange Book status of PHARMOBEDIENT?

Answer: Not determined.

Are there FDA-listed patents for PHARMOBEDIENT?

Not determined.

Which patent types appear (drug substance, drug product, method of use)?

Not determined.

What are the listed expiration dates and exclusivity end dates?

Not determined.

What patents protect PHARMOBEDIENT, and how strong is the patent estate?

Answer: Not determined.

How many patents cover PHARMOBEDIENT across composition, formulation, and use?

Not determined.

Who are the assignees of the key patents?

Not determined.

What jurisdiction coverage exists (US only vs. global families)?

Not determined.

When does PHARMOBEDIENT lose exclusivity or patent protection?

Answer: Not determined.

What are the expected earliest US launch dates for generics?

Not determined.

What exclusivity periods apply (NCE, 5-year, 3-year, pediatric, orphan)?

Not determined.

What is the timing risk for at-risk launches?

Not determined.

What generic entry risks exist for PHARMOBEDIENT, including Paragraph IV?

Answer: Not determined.

Have any Paragraph IV challenges been filed?

Not determined.

Which generic companies are potential challengers?

Not determined.

What settlement or consent judgments affect entry timing?

Not determined.

What formulations are protected by PHARMOBEDIENT patents?

Answer: Not determined.

Are there protected technologies (extended-release, tamper-resistant, particulate, co-crystal)?

Not determined.

Are manufacturing processes patented (drying, granulation, sterilization, aseptic fill-finish)?

Not determined.

What method-of-use patents protect PHARMOBEDIENT?

Answer: Not determined.

Are there line-extension indications (new dosing, patient subsets, combination regimens)?

Not determined.

What claim scopes are likely to be infringed by labeled use?

Not determined.

Which companies are challenging PHARMOBEDIENT, and what does litigation show?

Answer: Not determined.

What patent litigation affects PHARMOBEDIENT?

Not determined.

What are the key court dates and outcomes?

Not determined.

What patents were asserted, and against which generic applicants?

Not determined.

How does PHARMOBEDIENT compare with competing brands and generics?

Answer: Not determined.

What are the therapeutic alternatives and substitution patterns?

Not determined.

How do pricing and access differ among competitors?

Not determined.

Are there competitive differentiation levers (onset, safety, adherence, device delivery)?

Not determined.

What FDA regulatory pathway does PHARMOBEDIENT use, and how does it affect competitive entry?

Answer: Not determined.

Is it approved via 505(b)(1), 505(b)(2), or 505(j)?

Not determined.

Is there REMS, risk management, or restricted distribution?

Not determined.

Are there biosimilar-like risks (if PHARMOBEDIENT is a biologic)?

Not determined.

Commercial strategy: where is PHARMOBEDIENT exposed to revenue erosion?

Answer: Not determined.

What is the maturity of the market (new launch vs. entrenched)?

Not determined.

What are the most likely first-wave generic or switch drivers?

Not determined.

What payer pressures exist (PBM position, formulary status, prior auth)?

Not determined.

Key Takeaways

  • PHARMOBEDIENT cannot be connected to a specific US-regulated product, active ingredient, or FDA application based on the provided input.
  • No defensible analysis of Orange Book listings, exclusivity timelines, patent scope, Paragraph IV risk, litigation, or competitive substitution can be produced without a determinable drug identity.

FAQs

  1. How do I find the correct Orange Book record for a brand when the manufacturer is unclear?
  2. What is the typical patent coverage map for a US small-molecule brand (drug substance, drug product, method-of-use)?
  3. How does pediatric exclusivity interact with listed Orange Book patents for launch timing?
  4. What claim elements most often drive non-infringement or design-around arguments in Paragraph IV cases?
  5. What data points best predict generic erosion risk for an established brand (patent count, expirations, exclusivity end dates, litigation posture)?

References

  1. Not provided.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.